Interestingly, IL-4 expression increases surface IgM expression and reduces CXCR4 and CXCR5 and seems to render CLL cells resistant to BCR-signaling inhibitors ibrutinib and idelalisib [159]. The gene discussed is CXCR5; the disease is B-cell chronic lymphocytic leukemia.